<DOC>
	<DOCNO>NCT00280696</DOCNO>
	<brief_summary>A double-blind , randomize , multicenter , placebo control 5 parallel group , confirmatory trial evaluate efficacy safety levetiracetam use adjunctive treatment patient 16 65 year epilepsy suffer partial onset seizure .</brief_summary>
	<brief_title>A Double-blind Confirmatory Trial Levetiracetam Epilepsy Patients With Partial Onset Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Epileptic patient fulfill follow criterion eligible inclusion study : Subjects age 16 65 year acquisition inform consent trial participation Seizure type : subject epileptic seizure diagnose partial seizure 2 year ago accord `` Clinical electroencephalographic classification epileptic seizure ( 1981 ) '' define International League Against Epilepsy ( ILAE ) confirm EEG perform within 1 year Screening Screening Visit Subjects whose previous therapy screen involve least two standard antiepileptic drug ( AEDs ) partial seizure , confirm dos meet daily dose specify treatment epilepsy package insert therapy continue least 3 month Frequency epileptic seizure : subject experience partial seizure least 12 time 12 week Baseline Period ( Week âˆ’12 Week 0 ) least twice every 4 week The following patient eligible inclusion study : Subjects diagnose status epilepticus within 3 month screen Subjects partial seizure frequency measure Baseline Period Subjects underwent surgery epilepsy within 2 year Screening schedule undergo brain surgery study period within 4 week completion study Subjects history oral treatment Levetiracetam ( LEV )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Epilepsies , Partial ,</keyword>
	<keyword>Keppra , levetiracetam</keyword>
</DOC>